Is sermorelin approved or legal?

Sermorelin was FDA-approved (as Geref) for pediatric GH deficiency in 1997 but was withdrawn from the US market in 2008 for commercial reasons, not safety. It is still supplied through compounding pharmacies and used off-label for adults, but compounded products are not FDA-reviewed, and it is prohibited in sport by WADA. Material sold outside the compounding channel is for research use only.

How is sermorelin dosed and what is its half-life?

The former pediatric dose was about 30 mcg/kg/day subcutaneously at bedtime; adult studies used lower weight-based doses. Anecdotal off-label protocols cite roughly 100-300 mcg at bedtime, often with a GHRP. Its plasma half-life is very short (about 10-12 minutes), but it triggers a GH pulse peaking 30-60 minutes later. This is reference information, not dosing advice.

How is sermorelin different from injecting HGH?

Sermorelin stimulates the pituitary to release its own growth hormone, so the natural feedback loop and pulsatile pattern are preserved, which limits GH excess and reduces the acromegaly and chronic IGF-1 concerns associated with direct GH. It is generally milder, but its effect depends on a responsive pituitary.

Does sermorelin actually work?

For pediatric GH deficiency, yes - it was approved on the basis of randomized trials. In adults it raises GH and IGF-1 and produced modest body-composition improvements in small studies, but the anti-aging evidence is limited and dated, and large long-term trials of off-label use are lacking.

It was well tolerated in trials, with mild side effects such as injection-site reactions, flushing, and headache, and a lower theoretical tumor concern than exogenous GH because IGF-1 is not chronically elevated. However, long-term off-label safety is unstudied and compounded product quality can vary. It should be used only under medical supervision.

Hormonal

Sermorelin

Also known as: Sermorelin acetate, GHRH(1-29), GRF(1-29), Geref, Growth Hormone Releasing Factor 1-29

A synthetic 29-amino-acid fragment of GHRH that prompts the pituitary to release its own growth hormone; formerly FDA-approved for pediatric GH deficiency, now used off-label...

Last updated July 11, 2026

Buy Sermorelin

Overview

Sermorelin acetate is a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone, GHRH(1-29)-NH2. Although native GHRH is 44 amino acids long, its full agonist activity resides in this N-terminal fragment, so sermorelin reproduces GHRH's biological effect with a shorter molecule. It acts on the pituitary's GHRH receptor to stimulate release of the body's own growth hormone, rather than supplying GH directly. Sermorelin has an unusually strong clinical pedigree for a research peptide. It was developed as Geref and received FDA approval in 1997 for idiopathic growth-hormone deficiency in children with growth failure, supported by multicenter randomized trials. The manufacturer voluntarily withdrew it from the US market in 2008 for commercial (not safety) reasons. It continues to be supplied by compounding pharmacies in the US, is used clinically in some countries, and is widely used off-label for adult GH restoration and anti-aging. The distinction that matters is between its evidenced and unevidenced uses. The pediatric GH-deficiency data are robust; the adult anti-aging and body-composition evidence is real but limited to small, mostly 1990s studies, with no large long-term trials of off-label use. Compounded formulations have not undergone the same regulatory scrutiny as the original approved product, and sermorelin is prohibited in sport by WADA. Material sold outside the compounding channel is labeled for research use only. This entry summarizes the published science and community-reported practice for reference only. It is not medical advice and does not endorse non-prescribed human use.

How it works

Sermorelin binds and activates the GHRH receptor (GHRHR), a Gs-protein-coupled receptor on the somatotroph cells of the anterior pituitary. Activation raises intracellular cAMP, triggering pulsatile release of stored endogenous growth hormone. Because the stimulus acts upstream on the pituitary, the body's own negative-feedback loop (via IGF-1 and somatostatin) stays intact, which tends to limit supraphysiological GH excursions and preserve the natural pulsatile, diurnal pattern - a key contrast with directly injected recombinant GH. Sermorelin does not act at the ghrelin receptor (GHS-R1a), so its mechanism is distinct from the GHRPs; however, co-administering a GHRP (which suppresses somatostatin tone and activates GHS-R1a independently) produces additive or synergistic GH release, which is the rationale for GHRH/GHRP stacking.

Researched effects

Clinical Accelerates growth in children with idiopathic growth-hormone deficiency (former FDA-approved indication)
Clinical Increases endogenous GH secretion and raises IGF-1 in adults
Clinical Improves lean body mass and reduces fat mass over months of bedtime dosing in older adults
Clinical Preserves natural GH pulsatility and pituitary feedback, unlike exogenous GH
Clinical Synergizes with GHRP-2 or GHRP-6 to amplify GH release
Anecdotal Improved sleep, recovery, skin, and vitality with off-label anti-aging use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

Established for its former pediatric indication. The FDA-approved pediatric dose was about 30 mcg/kg/day subcutaneously, given at bedtime to coincide with the natural nocturnal GH peak. Adult studies have used lower, weight-based doses - on the order of 0.5-3 mcg/kg subcutaneously at bedtime (one influential trial used a closely related analog, [Nle27]GHRH(1-29)-NH2, at about 2 mcg/kg/day for six months). Bedtime timing is consistently emphasized because it augments the dominant nocturnal GH pulse.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community and off-label sources commonly describe fixed subcutaneous doses of roughly 100-300 mcg (most often around 200 mcg) at bedtime, frequently stacked with GHRP-2 or GHRP-6 (each ~100-300 mcg) for synergistic GH release, in cycles of about 3-6 months. It is often framed as a gentler, lower-cost alternative to exogenous GH because pituitary feedback is preserved. These figures reflect unverified community practice rather than tested safe or effective doses.

Half-life: Very short in plasma - roughly 10-12 minutes after intravenous administration, with subcutaneous dosing extending the effect curve only modestly because the peptide is rapidly degraded. Despite this rapid clearance it triggers a robust GH pulse that typically peaks 30-60 minutes after injection, which in turn drives IGF-1 production over the following hours.
Routes: subcutaneous, intravenous, intranasal

Safety & side effects

Sermorelin was well tolerated in both pediatric trials and adult studies. The most common adverse effects are injection-site reactions (redness, pain, swelling), transient facial flushing, and headache. Because it works upstream and the pituitary feedback loop stays intact, it does not produce the GH-excess (acromegalic) picture associated with high-dose exogenous GH, and chronic IGF-1 elevation - and its theoretical tumor-promotion concern - is less pronounced. Glucocorticoids can blunt the GHRH response. Long-term safety of adult off-label use has not been established in large trials, and compounded products have not undergone the regulatory scrutiny of the original approved drug, so purity and potency can vary. Sermorelin is prohibited in sport by WADA. This information is for research reference only and is not a recommendation for non-prescribed human use.

Research summary

Sermorelin is among the better-evidenced compounds in the research-peptide space. Its FDA approval required multicenter randomized trials in pediatric GH deficiency, giving it a clinical dossier substantially larger than that of the GHRPs, BPC-157, or TB-500. Its mechanism - GHRH-receptor activation driving pulsatile, feedback-regulated endogenous GH release - is well characterized, as is its very short plasma half-life paired with a durable downstream GH and IGF-1 response. The adult and anti-aging evidence is genuine but thinner. Small randomized trials in older adults (and a companion trial using a closely related GHRH analog) reported restored IGF-1, gains in lean mass, and reductions in fat over six to twelve months, and review articles have argued sermorelin may be preferable to direct GH for adult-onset GH insufficiency because feedback is preserved. However, these studies are small and mostly from the 1990s, and there are no large long-term trials of contemporary off-label use; current compounded formulations also differ from the studied product. The honest assessment is that sermorelin is a well-validated GH secretagogue for diagnosed GH deficiency and a mechanistically attractive, relatively gentle option for raising endogenous GH, but its anti-aging and body-composition benefits in healthy adults are only modestly supported and its long-term off-label safety is not established. It should be treated as a research compound outside its approved medical context.

FAQ

Is sermorelin approved or legal?: Sermorelin was FDA-approved (as Geref) for pediatric GH deficiency in 1997 but was withdrawn from the US market in 2008 for commercial reasons, not safety. It is still supplied through compounding pharmacies and used off-label for adults, but compounded products are not FDA-reviewed, and it is prohibited in sport by WADA. Material sold outside the compounding channel is for research use only.
How is sermorelin dosed and what is its half-life?: The former pediatric dose was about 30 mcg/kg/day subcutaneously at bedtime; adult studies used lower weight-based doses. Anecdotal off-label protocols cite roughly 100-300 mcg at bedtime, often with a GHRP. Its plasma half-life is very short (about 10-12 minutes), but it triggers a GH pulse peaking 30-60 minutes later. This is reference information, not dosing advice.
How is sermorelin different from injecting HGH?: Sermorelin stimulates the pituitary to release its own growth hormone, so the natural feedback loop and pulsatile pattern are preserved, which limits GH excess and reduces the acromegaly and chronic IGF-1 concerns associated with direct GH. It is generally milder, but its effect depends on a responsive pituitary.
Does sermorelin actually work?: For pediatric GH deficiency, yes - it was approved on the basis of randomized trials. In adults it raises GH and IGF-1 and produced modest body-composition improvements in small studies, but the anti-aging evidence is limited and dated, and large long-term trials of off-label use are lacking.
Is sermorelin safe?: It was well tolerated in trials, with mild side effects such as injection-site reactions, flushing, and headache, and a lower theoretical tumor concern than exogenous GH because IGF-1 is not chronically elevated. However, long-term off-label safety is unstudied and compounded product quality can vary. It should be used only under medical supervision.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.